Adamas Pharma (ADMS) Misses Q4 EPS by 9c

Adamas Pharma (NASDAQ: ADMS) reported Q4 EPS of ($1.27), $0.09 worse than the analyst estimate of ($1.18). Revenue for the quarter came in at $568 thousand versus the consensus estimate of $840 thousand.

For earnings history and earnings-related data on Adamas Pharma (ADMS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance